You can buy or sell Haemonetics and other stocks, options, ETFs, and crypto commission-free!
Haemonetics Corporation, also called Haemonetics, is a healthcare company, which engages in the development and distribution of hematology products and solutions. It operates through the following geographical segments: Japan, EMEA (Europe, the Middle East, and Africa), North America Plasma, and All Other. Read More Its products include surgical and diagnostic devices, blood and plasma center devices, blood center software, hospital software, and plasma center software. The company was founded by Allen Latham, Jr. in 1971 and is headquartered in Braintree, MA.
52 Week High
52 Week Low
Latest Technicals: Haemonetics Corporation (NYSE: HAE)
Haemonetics Corporation trades as part of the healthcare sector and medical instruments and equipment industry. The company CEO is Christopher Simon. Haemonetics Corp is a health care company. It provides products enabling in the processing, handling and analysis of blood and portfolio of integrated devices and information management tools to improve clinical outcomes. Previous Intraday Trading Performance: The HAE stock showed a previous change of 0.73% with an open at 87.38 and a close of 87.94. It reac...
Yahoo FinanceMar 12
Haemonetics' Plasma Unit Grows, Global Expansion on Track
On Mar 11, we issued an updated research report on Haemonetics Corporation HAE. The company has been witnessing strong growth in Plasma and Hemostasis Management units for quite some time now.
Yahoo FinanceMar 7
Why Is Haemonetics (HAE) Down 1.4% Since Last Earnings Report?
Haemonetics (HAE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. A month has gone by since the last earnings report for Haemonetics (HAE). Shares have lost about 1.4% in that time frame, underperforming the S&P 500. Will the recent negative trend continue leading up to its next earnings release, or is Haemonetics due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most rec...
Expected May 7, Pre-Market